Integrating genomic mutations and tumor-infiltrating lymphocytes improves prediction of response to trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer

Abstract

Aim: Resistance to trastuzumab remains a major barrier to cure in early-stage HER2-positive breast cancer (HER2+ BC). We investigated the impact of genomic alterations and tumor-infiltrating lymphocyte (TIL) density on treatment resistance and survival outcomes.

Methods: We retrospectively analyzed 315 patients with HER2+ BC who received adjuvant trastuzumab at Ruijin Hospital (2009-2019). Whole-exome sequencing and TIL scoring were performed on surgical specimens, and clinical and pathological data were collected. The Cancer Genome Atlas (TCGA) cohort was used for external validation. Genomic alterations and TIL density were compared between trastuzumab-sensitive and -resistant tumors. Survival analyses were conducted to identify prognostic biomarkers.

Results: After a median follow-up of 109.3 months, 67 tumors (21.3%) were trastuzumab-resistant, exhibiting lower TIL density (mean 19.8% vs. 26.3%, P = 0.001), higher mutation frequencies in FLG, MAP1A, BRCA1, PTPRD, PAPPA2, NCOR2, FBXW7, MYH7, and VCAN, and more frequent alterations in the TP53/NOTCH pathways compared with sensitive tumors (all P < 0.05). A 15-gene trastuzumab response-associated gene (TRAG) signature independently predicted poorer disease-free survival (DFS) in both our cohort (HR, 3.57, P < 0.001) and the TCGA cohort (HR, 4.99, P = 0.037). A high copy number alteration burden was associated with worse overall survival (HR, 2.49, P = 0.043), whereas TIL density > 10% was associated with improved DFS (HR, 2.44, P = 0.003). A prognostic model integrating tumor size, nodal status, estrogen receptor status, TILs, and the TRAG signature showed strong discriminatory power (c-index 0.743 in the training set; 0.915 in the validation set).

Conclusion: Genomic alterations and reduced TIL density underpin trastuzumab resistance. The novel TRAG signature and integrated prognostic model enhance risk stratification and may guide personalized adjuvant therapy in early-stage HER2+ BC.

Keywords

Breast neoplasms / genomic mutation / tumor-infiltrating lymphocytes / survival / models

References

[1] Siegel RL,Giaquinto AN,Jemal A.Cancer statistics, 2025.CA Cancer J Clin2025;75:10-45 PMCID:PMC11745215

[2] Swain SM,Hamilton E.Targeting HER2-positive breast cancer: advances and future directions.Nat Rev Drug Discov2023;22:101-26 PMCID:PMC9640784

[3] Choong GM,O’Sullivan CC.Evolving standards of care and new challenges in the management of HER2-positive breast cancer.CA Cancer J Clin2020;70:355-74

[4] Tarantino P,Parsons HA.Aiming at a tailored cure for ERBB2-positive metastatic breast cancer: a review.JAMA Oncol2022;8:629-35

[5] Dong C,Chen Y,Chen C.Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer.Front Pharmacol2021;12:628690 PMCID:PMC8005514

[6] Triulzi T,De Cecco L.Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit.Br J Cancer2018;119:1487-94 PMCID:PMC6288086

[7] Kumagai S,Nishikawa H.Antitumour immunity regulated by aberrant ERBB family signalling.Nat Rev Cancer2021;21:181-97

[8] Low SK,Nakamura Y.Breast cancer: the translation of big genomic data to cancer precision medicine.Cancer Sci2018;109:497-506 PMCID:PMC5834810

[9] Zakaria NH,Saied MH,Elkayal A.Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy.Hum Genomics2023;17:43 PMCID:PMC10193616

[10] Pohlmann PR,Mernaugh R.Resistance to trastuzumab in breast cancer.Clin Cancer Res2009;15:7479-91 PMCID:PMC3471537

[11] Li Q,Zhang Y,Chen S.A new wave of innovations within the DNA damage response.Signal Transduct Target Ther2023;8:338 PMCID:PMC10485079

[12] Loibl S,Guarneri V.PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.Ann Oncol2016;27:1519-25 PMCID:PMC6279074

[13] Pietrantonio F,Bellomo SE.HER2 copy number and resistance mechanisms in patients with HER2-positive advanced gastric cancer receiving initial trastuzumab-based therapy in JACOB trial.Clin Cancer Res2023;29:571-80 PMCID:PMC9890129

[14] Baselga J.Treatment of HER2-overexpressing breast cancer.Ann Oncol2010;21 Suppl 7:vii36-40

[15] Salgado R,Campbell C.Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial.JAMA Oncol2015;1:448-54 PMCID:PMC5551492

[16] Collins GS,Dhiman P.TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods.BMJ2024;385:e078378 PMCID:PMC11019967

[17] Shu L,Li Z,Shen K.Can HER2 1+ breast cancer be considered as HER2-low tumor? A comparison of clinicopathological features, quantitative HER2 mRNA levels, and prognosis among HER2-negative breast cancer.Cancers2022;14:4250 PMCID:PMC9455006

[18] Allison KH,Dowsett M.Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update.J Clin Oncol2020;38:1346-66

[19] Wolff AC,Allison KH.Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.J Clin Oncol2018;36:2105-22

[20] Salgado R, Denkert C, Demaria S, et al; International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259-71. PMCID:PMC11288342

[21] Tolaney SM,White J.Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0.J Clin Oncol2021;39:2720-31 PMCID:PMC10166345

[22] Wong H,Kwong A.Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer.Oncologist2011;16:1535-46 PMCID:PMC3233287

[23] Sanchez-Vega F, Mina M, Armenia J, et al; Cancer Genome Atlas Research Network. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell. 2018;173:321-37.e10. PMCID:PMC6070353

[24] Färkkilä A,Oikkonen J.Heterogeneity and clonal evolution of acquired PARP inhibitor resistance in TP53- and BRCA1-deficient cells.Cancer Res2021;81:2774-87 PMCID:PMC8323804

[25] Viansone A,Omarini C.Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer.Breast2022;65:145-50 PMCID:PMC9399365

[26] Huang X,Meng Q.Protein tyrosine phosphatase receptor type D (PTPRD)-mediated signaling pathways for the potential treatment of hepatocellular carcinoma: a narrative review.Ann Transl Med2020;8:1192 PMCID:PMC7576031

[27] Shah D.Cancer stem cells and HER2 positive breast cancer: the story so far.Genes Dis2016;3:114-23 PMCID:PMC6095671

[28] Chakrabarty A,Sutton C.Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.Cancer Res2013;73:1190-200 PMCID:PMC3563941

[29] Dong Y,Duan J.PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.Cell Prolif2022;55:e13283 PMCID:PMC9436912

[30] Poddar A,Rao SR.The role of pregnancy associated plasma protein-A in triple negative breast cancer: a promising target for achieving clinical benefits.J Biomed Sci2024;31:23 PMCID:PMC10885503

[31] Lu Y,Zhao Y,Pollak M.Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).J Natl Cancer Inst2001;93:1852-7

[32] Ticha P,Kersten K.NCOR2 represses MHC class I molecule expression to drive metastatic progression of breast cancer.bioRxiv2025; PMCID:PMC11952456

[33] Jiang BH.Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.Drug Resist Updat2008;11:63-76 PMCID:PMC2519122

[34] Chen S,Zhao J.FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy.Front Oncol2023;13:1147239 PMCID:PMC10043335

[35] Balamurugan K,Sharan S.C/EBPδ links IL-6 and HIF-1 signaling to promote breast cancer stem cell-associated phenotypes.Oncogene2019;38:3765-80 PMCID:PMC6437025

[36] Yicheng F,Tian Y.Association of FLG mutation with tumor mutation load and clinical outcomes in patients with gastric cancer.Front Genet2022;13:808542 PMCID:PMC9421250

[37] Mitsui Y,Kato T.Versican promotes tumor progression, metastasis and predicts poor prognosis in renal carcinoma.Mol Cancer Res2017;15:884-95 PMCID:PMC5890926

[38] Arichi N,Hiraki M.Versican is a potential therapeutic target in docetaxel-resistant prostate cancer.Oncoscience2015;2:193-204 PMCID:PMC4381710

[39] Osipo C,Rizzo P.ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.Oncogene2008;27:5019-32

[40] Pandya K,Clementz AG.Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.Br J Cancer2011;105:796-806 PMCID:PMC3171020

[41] Nik-Zainal S,Staaf J.Landscape of somatic mutations in 560 breast cancer whole-genome sequences.Nature2016;534:47-54 PMCID:PMC4910866

[42] Zwimpfer TA,Coelho R.TP53 mutations and phosphatidylinositol 3-kinase/AKT pathway alterations are key determinants of breast cancer outcome independent of subtype and stage.JCO Precis Oncol2025;9:e2400767 PMCID:PMC12122097

[43] Dieci MV,Bisagni G.Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.Ann Oncol2019;30:418-23 PMCID:PMC6442655

[44] Kim RS,Gavin PG.Stromal tumor-infiltrating lymphocytes in NRG oncology/NSABP B-31 adjuvant trial for early-stage HER2-positive breast cancer.J Natl Cancer Inst2019;111:867-71 PMCID:PMC6695304

[45] Musolino A,Bortesi B.Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.J Clin Oncol2008;26:1789-96

[46] Seo AN,Kim EJ.Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer.Br J Cancer2013;109:2705-13 PMCID:PMC3833219

[47] Mahmoud SM,Powe DG.Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.J Clin Oncol2011;29:1949-55

[48] Bates GJ,Han C.Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.J Clin Oncol2006;24:5373-80

[49] West NR,Martin SD.Tumour-infiltrating FOXP3⁺ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer.Br J Cancer2013;108:155-62 PMCID:PMC3553524

[50] Gu-Trantien C,Garaud S.CD4⁺ follicular helper T cell infiltration predicts breast cancer survival.J Clin Invest2013;123:2873-92 PMCID:PMC3696556

[51] Teschendorff AE,Arenas A.Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules.BMC Cancer2010;10:604 PMCID:PMC2991308

[52] Vanni S,Cusano AM.Engineered anti-HER2 drug delivery nanosystems for the treatment of breast cancer.Nanoscale2025;17:9436-57